QURE—One reason for the recent sell-off could be skepticism about pricing of gene-therapy products. Here’s an excerpt from the Reuters piece in #msg-96847475 (from 2/5/14, the day of QURE’s US IPO):
Does your calculation of the $60M enterprise value take into account dilution from options and warrants? If so, the $60M EV does seem unduly cheap, IMO.
See the links in #msg-96429741 for related info on gene-therapy pricing.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.